Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Michael Birrer to Camptothecin

This is a "connection" page, showing publications Michael Birrer has written about Camptothecin.

 
Connection Strength
  
 
 
0.321
  
  1. Krasner CN, Campos SM, Young CL, Chadda KR, Lee H, Birrer MJ, Horowitz NS, Konstantinopoulos PA, D'Ascanio AM, Matulonis UA, Penson RT. Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer. Gynecol Oncol. 2021 09; 162(3):661-666.
    View in: PubMed
    Score: 0.196
  2. Pham E, Birrer MJ, Eliasof S, Garmey EG, Lazarus D, Lee CR, Man S, Matulonis UA, Peters CG, Xu P, Krasner C, Kerbel RS. Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer. Clin Cancer Res. 2015 Feb 15; 21(4):808-18.
    View in: PubMed
    Score: 0.125
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.